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Abstract: Demand of scaffolds for hard tissue repair increases due to a higher incidence of fractures
related to accidents and bone-diseases that are linked to the ageing of the population. Namely,
scaffolds loaded with bioactive agents can facilitate the bone repair by favoring the bone integration
and avoiding post-grafting complications. Supercritical (sc-)foaming technology emerges as a unique
solvent-free approach for the processing of drug-loadenu7d scaffolds at high incorporation yields. In
this work, medicated poly(ε-caprolactone) (PCL) scaffolds were prepared by sc-foaming coupled
with a leaching process to overcome problems of pore size tuning of the sc-foaming technique. The
removal of the solid porogen (BA, ammonium bicarbonate) was carried out by a thermal leaching
taking place at 37 ◦C and in the absence of solvents for the first time. Macroporous scaffolds with
dual porosity (50–100 µm and 200–400 µm ranges) were obtained and with a porous structure directly
dependent on the porogen content used. The processing of ketoprofen-loaded scaffolds using BA
porogen resulted in drug loading yields close to 100% and influenced its release profile from the
PCL matrix to a relevant clinical scenario. A novel solvent-free strategy has been set to integrate the
incorporation of solid porogens in the sc-foaming of medicated scaffolds.
Keywords: scaffolds; supercritical CO2; foaming; solvent-free processing; ketoprofen; porogen
1. Introduction
Ageing of the population represents a major concern for the sustainability of the
healthcare system. In Europe, the proportion of elderly people (aged 65 years and over)
is expected to increase from 19% to 29% by 2070, coupled with a severe rise of 12% for
people aged 80 and above [1]. At the same time, a drop of the working-age population of
ca. 10% is prospected, thus representing a moderate share of the entire population. New
biomedical technologies and approaches are thus requested to prompt longer working lives
and healthier workers to mitigate the ageing burden. Namely, accidental and bone-diseases
related fractures have a particular impact in the wellness and mobility of elderly people,
leading to devastating physical and mental consequences that preclude the possibility of
recovering the preceding welfare status of the patient [2].
Bone is the second most common transplantation tissue and its current gold-standard
surgical procedure (implantation of biological grafts) is not exempt from clinical compli-
cations like immune rejection, risk of infections, and sequelae [3,4]. The advent of the
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regenerative medicine field facilitated the development of synthetic biodegradable grafts,
known as scaffolds, offering a promising outlook for the full recovery of bone functionality.
Scaffolds have been prepared from many biomaterials, including metals, ceramics, and
a portfolio of biocompatible polymers [5,6]. The choice of biodegradable polymers is of
preference since the response of the scaffolds to the biological environment favors gradual
degradation rates of the scaffolds aiming to match the tissue regeneration tempos. In
addition, the incorporation of bioactive agents (e.g., anti-inflammatory drugs and growth
factors) to the synthetic grafts can improve the integration of the scaffolds to the surround-
ing biological environment and mitigate post-surgical comorbidities such as excessive
inflammation, pain, or the risk of infections [7–11].
Among the manufacturing techniques for the preparation of polymeric scaffolds,
the supercritical CO2-assisted foaming, the so-called supercritical (sc-) foaming, offers
significant advantages regarding the solvent-free processability of materials and the loading
of bioactive compounds in an integrated process and at high yields [12]. The sc-foaming
technique relies on two main sequential steps: (1) CO2 sorption in the polymeric matrix
under a target working temperature and pressure, and (2) controlled pressure reduction
with pore formation. Porosity is generated in these structures through a nucleation-growth
mechanism taking place due to the sudden supersaturation of CO2 in the polymer as
the pressure decreased. The CO2 escape from the matrix leads to the vitrification of the
polymer, stabilizing the formed porous structure [13]. The pressure-dependent plasticizing
effect of CO2 allows the processing of polymers under mild temperatures, thus unlocking
the possibility of an in situ incorporation of thermolabile compounds, such as growth
factors, with low degradation and activity losses [14]. Moreover, the safety of use of carbon
dioxide (low toxicity) and its recyclability makes it a green technology with the associated
environmental benefits.
The preparation of scaffolds using the sc-foaming method allows the tuning of their
porous morphology (porosity, mean pore size, and pore size distribution) to fit certain
target specifications [15]. Processing temperature and pressure, CO2 contact time and
depressurization rate are the main foaming parameters able to adjust the pore size and
homogeneity [16,17]. However, the limitations of sc-foaming are related to the complex
modelling of the pore formation mechanisms to get a precise control and predictability of
the pore sizes and distributions obtained for the processed scaffolds. Moreover, the use of
depressurization gradients [18] and leaching methods with particulate porogens (e.g., NaCl,
sucrose, carbonates, bicarbonates, zein [19–26]), and sacrificial polymers [27] within this
foaming process can result in scaffolds with more open porosity and dual macroporosity
(i.e., porous materials with two pore families in the macroporous range) [19,28]. The use
of porogens is the most suitable approach to reach an additional macropore family with
well-defined porosity and narrow pore size distribution, although an extra processing step
will be usually needed to remove the porogen by solvent (usually water) leaching and
the advantageous solvent-free property of sc-foaming technique is thus omitted [12,29].
In the case of drug-loaded scaffolds, the leaching of the bioactive agent contained in the
scaffold formulations may take place along with the porogen removal resulting in dramatic
reductions in drug incorporation yields [29,30]. Overall, novel strategies are needed to
align the incorporation of solid porogens in the sc-foaming of medicated scaffolds.
Medicated scaffolds obtained by sc-foaming and using a porogen that can be removed
without any solvent leaching process involved were herein produced. In this work, scaf-
folds medicated with drugs were prepared by sc-foaming using ammonium bicarbonate
(AB) porogen. AB was the selected porogen since it can be removed through thermal degra-
dation at temperatures as low as 35–40 ◦C [31,32], compatible with thermally sensitive
compounds. Ketoprofen, a nonsteroideal anti-inflammatory drug (NSAID) commonly
used for pain relief and to reduce inflammation occurring post-implantation [33], was
herein selected as model drug within the scaffold formulation for local administration. This
local treatment will avoid the common gastrointestinal disorders linked to the systemic
ketoprofen administration by oral delivery [34]. The effect of this processing strategy on the
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physicochemical properties of the scaffolds, on the drug loading yield and on cytocompati-
bility was evaluated. Finally, the effect of the use of this porogen on the release profiles of
the ketoprofen-loaded polymeric scaffolds was determined. To the best of our knowledge,
this is the firstly reported solvent-free approach incorporating the use of solid porogen
particles to induce a new macropore population in scaffolds obtained by sc-foaming.
2. Results and Discussion
2.1. Scaffolds Development and Morphological Characterization
Tissue regeneration requires scaffolds with a suitable porous structure, usually in
the 60–80% porosity range and with interconnected macropores of sizes of 75 µm and
above to facilitate cell colonization and growth [35]. The ultimate goal of the scaffold is
to promote the generation of a mature biological tissue after a certain post-implantation
period (in the order of months or even years). These specific porous features can be
achieved in thermoplastic polymers through the sc-foaming process, which is assisted by
the plasticizing effect of compressed CO2. In the case of the poly(ε-caprolactone) (PCL) used
in this work, the biopolymer had a melting point depletion upon contact with pressurized
CO2 at 140 bar of more than 20 ◦C with respect to its normal melting point (61.4 ◦C).
Accordingly, molten PCL polymer was obtained at 37 ◦C in a supercritical CO2 atmosphere
after a certain time period (point C in Figure 1a). This low processing temperature used in
the sc-foaming technique is unbeatable by any other alternative thermal-based foaming
method (e.g., melt-molding, melt extrusion, and fused deposition modelling).
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Figure 1. Development of poly(ε-caprolactone) (PCL) scaffolds through the sc-foaming method: 
(a) Typical pressure (P) vs. time (t) profile of sc-foaming tests performed in this work with PCL 
scaffolds. For certain cases, a visual inspection (pictures at the bottom) of the physical phenomena 
taking place during the sc-foaming steps (I. pressurization, II. Soaking, and III. depressurization) 
was carried out: (A) raw PCL powder before CO2 pressurization, (B) CO2 solubilization in PCL, (C) 
polymer melting, and (D) polymeric expansion and formation of pores. (b) SEM images of a PCL 
i r . Development of poly(ε-caprolactone) (PCL) scaffolds throug the sc-foaming method:
( ) vs. time (t) profile of sc-foaming tests performed in this work with PCL
ff l . t i s, is al i s ection (pictures at the botto ) of the physical phenomena
taking place during the sc-foaming steps (I. pressurization, II. Soaking, and III. depressurization)
was carried out: (A) raw PCL powder before CO2 pressurization, (B) CO2 solubilization in PCL,
(C) polymer melting, and (D) polymeric expansion and formation of pores. (b) SEM images of a
PCL scaffold processed by sc-foaming at 37 ◦C and 140 bar with a soaking time of 1 h and slow
depressurization (3 bar/min). Scale bars: 100 µm.
During the depressurization stage of the sc-foaming process, CO2 is vented out of the
polymeric structure in a controlled way leading to PCL vitrification and the formation of a
macroporous foam (point D in Figure 1a,b). Pore size of the scaffolds can be modulated up
to a certain extent by the depressurization rate with lower values favoring the formation
of larger pores [16,36–38]. Using this approach, PCL scaffolds with high porosity (63%)
presenting macropores with smooth surfaces and 80% interconnectivity were obtained
(Figure 1b and Table 1). Overall, sc-foaming technology opens up new processing pos-
Polymers 2021, 13, 159 4 of 15
sibilities to obtain scaffolds at low operating temperatures allowing the feasibility of the
production of polymeric foams incorporating thermally-sensitive bioactive agents.
Table 1. Composition (expressed in weight percentage) of the initial mixtures used for the scaffold
formulations and textural properties of the resulting macroporous ketoprofen-loaded PCL scaffolds
by sc-foaming combined with BA porogen leaching.












PCL(0K)0BA 100 - - 0.41 ± 0.01 1.126 ± 0.015 63.6 ± 1.0
PCL(5K)0BA 95.0 5.0 - 0.51 ± 0.08 1.098 ± 0.004 53.6 ± 7.3
PCL(0K)50BA 50.0 - 50.0 0.24 ± 0.01 1.110 ± 0.011 78.4 ± 0.5
PCL(5K)50BA 47.4 2.6 50.0 0.29 ± 0.04 1.032 ± 0.006 71.9 ± 3.4
PCL(10K)50BA 47.4 5.3 50.0 0.28 ± 0.07 1.023 ± 0.009 72.6 ± 4.4
PCL(0K)75BA 25.0 - 75.0 0.20 ± 0.01 1.086 ± 0.006 81.6 ± 0.6
PCL(5K)75BA 23.7 1.3 75.0 0.18 ± 0.05 1.047 ± 0.005 82.8 ± 3.6
PCL(10K)75BA 22.4 2.6 75.0 0.18 ± 0.07 1.034 ± 0.007 82.6 ± 4.1
The compatibility of the scaffold processing method used with the incorporation of
bioactive compounds in the scaffold formulations was tested using ketoprofen, a hydropho-
bic NSAID with high affinity to the PCL matrix. The drug loading yield was close to 100%
since the remaining weight of the scaffold after the foaming process corresponded to the
sum of the initial weights of PCL and ketoprofen. The addition of ketoprofen resulted
in a densification of the scaffolds (PCL(5K)0BA scaffold in Table 1) with lower porosities
(54%) and pore interconnectivity (65%). The melting point of the PCL was reduced in the
presence of ketoprofen (Table A1). This effect was related to PCL-ketoprofen chemical
interactions and not to the processing method as this variation in the melting event was
also observed after the second DSC-heating cycle [39].
The use of BA porogen in the sc-foaming of medicated scaffolds and their subsequent
removal by a leaching process in the absence of liquid solvents was tested. The elimination
of this porogen was carried out at 37 ◦C and under vacuum to favor the thermal degradation
of BA into gaseous ammonia and carbon dioxide and at temperatures well below the normal
melting point of the PCL [20,29,40]. The thermal leaching process used in this work for
porogen removal would then surrogate the conventional solvent-based leaching process.
The removal of the porogen by vacuum heating just after the foaming process was complete
after a 10-day treatment according to the observed scaffold weight losses (data not shown).
The use of vacuum accelerated the porogen degradation in more than four days with
respect to the use of atmospheric drying. After this thermal post-processing, the melting
point of PCL was almost unaltered (61–62 ◦C) and its crystallinity increased from 60%
to 71–75% with respect to PCL scaffolds obtained by the same foaming conditions and
without thermal post-treatment (Table A1). BA might act as a secondary nucleation site
for PCL crystallization during the sc-foaming process as observed with other particle
admixtures [14].
The incorporation of BA as a porogen in the scaffold formulation assisted the sc-foaming
process to obtain scaffolds with customized porosity (Table 1). The use of porogen in 50 and
75 wt.% of the total initial mixture formulation resulted in dramatic increases of the overall
porosities in ca. 15 and 18%, respectively. The increase in the porosity of the scaffolds with a
higher BA content was also observed with scaffolds processed by phase inversion followed
by leaching of BA [29,40]. The maximum possible content of BA in the formulations was set
at 75% since higher porogen contents resulted in very brittle porous materials.
SEM imaging unveiled a change of porous morphology with the use of BA porogen
consisting on the presence of a second pore family of large macropores in the 200–400 µm
size range, i.e., of similar size to the porogen size (Figure 2a–c), along with a pore family in
the 50–100 µm size range related to the plasticizing and porogenic effects of compressed
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CO2. This new macroporous family falls in the optimum pore size of 325 µm for bone tissue
engineering, where the lower cell adhesion with respect to smaller pores is compensated
by an enhanced cell migration [35,41]. No remnants of BA particles were observed in
the SEM pictures confirming the full porogen removal. Interestingly, the scaffolds pre-
sented interconnected pores through throats in the order of 50–150 µm (white arrows in
Figure 2c,f,i). Ketoprofen was fully incorporated in the polymeric matrix of the scaffolds
and drug crystals were not observed. Ketoprofen can be molecularly dispersed or in the
amorphous form within the PCL-based scaffolds [42]. The presence of ketoprofen did not
interfere with the pore formation process upon sc-foaming and similar porous structures
were obtained for the PCL scaffolds loaded with 5 and 10 wt.% of the drug (Figure 2d–i).
Finally, the proportion of the family of large macropores in the 200–400 µm range increased
with a higher BA content (Figure 3), thus supporting the origin of these pores due to the
presence of the porogen.
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Figure 2. SE -i ages of cross sections of (a–c) PCL(0K)50BA, (d–f) PCL(5K)50BA, and (g–i) PCL(10K)50BA poly eric
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The mechanical properties of PCL scaffolds were tested under uniaxial compression
tests (Figure 4). Young’s moduli were in the 1 to 5 MPa range, depending on the scaffold
formulation, which is coherent for the intended application [43]. Higher porogen contents
during the scaffold processing reduced the mechanical properties, and scaffolds processed
with the highest BA content were significantly softer (Figure 4). The effect of porosity on
the mechanical performance of the materials is highly dependent on the pore sizes. Pores
in the microporous or low mesoporous range do not have a high effect on the mechanical
properties of the material [44,45]. In the case of macroporous materials, they usually exhibit
a power-law scaling relationship between Young’s modulus and the bulk density [46]. The
induction of the new macropore population in the PCL scaffolds reduced the bulk density
and, therefore, reduced the mechanical performance of the scaffolds.
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Des ite the ketoprofen incorporation had no impact on the morphology of the scaf-
folds, the viscoelastic behavior was remarkable modified (Figure 4). Regardless of the
porogen content, scaffold formulations processed with ketoprofen presented plastic defor-
mations of ca. 20% that are not observed in the unloaded scaffolds (black lines in Figure 4).
The ketoprofen incorporation effect on the mechanical properties was consistent and also
identified for formulations with higher porogen contents.
2.2. Ketoprofen Release Studies
The effect of ketoprofen entrapment into the PCL scaffolds by sc-foaming coupled to
the effect of porogen content on the capacity of modulation of the drug release kinetics
were evaluated in PBS pH 7.4 medium (Figure 5). After a lag time of ca. 30 min, all the
tested ketoprofen-loaded scaffolds provided a fast initial release, reaching ca. 70% of
dissolved ketoprofen at 24 h, followed by a more sustained release in the following days.
Ketoprofen release was stabilized after one week reaching a drug payload above 90% in
all cases. Complete drug release was obtained after three weeks for all the formulations.
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The drug contents dissolved in PBS medium after three weeks matched those of the
initial drug content in the formulations before the foaming-plus-leaching process, thus
confirming ketoprofen loading yields in the scaffolds close to 100%. The release profile of
these medicated scaffolds is of clinical relevance since it would provide anti-inflammatory
responses during the bone healing process through a fast action in the first hours after
implantation and keeping a certain drug local concentration at least during one week [47].
Moreover, the ketoprofen content per scaffold (65–130 mg) falls in-between the approved
doses (200 mg) upon oral administration for systemic delivery and the doses in patches
(30–100 mg) for local delivery [34] The obtained versatility in ketoprofen content within
the sc-foamed bone scaffolds opens up the possibility of delivering the required doses to
bone defects of different sizes.
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angles), PCL(10K)50BA (white triangles), PCL(5K)75BA (black circles), and PCL(10K)75BA (white circles). 
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Scaffolds were evaluated regarding their porous structures and weight losses after 
21 days in PBS pH 7.4 medium. Weight losses in the scaffolds were higher than those 
assigned to the release of the drug payload (Figure 6). This discrepancy in weight was 
related to PCL degradation and erosion and was higher for PCL(10K)50BA and 
PCL(10K)75BA scaffolds with higher drug contents (10 wt.%). PCL erosion takes place 
through hydrolytic chain scission of the ester groups and the process is favored with 
higher porosities [50,51]. 
Figure 5. Ketoprofen release from PCL-based scaffolds in PBS pH 7.4 at 37 ◦C and 60 rpm during 7 days (left) and close up of
the profiles during the first hours (right). Lines correspond to the fitting of the experimental data to the Korsm yer-Peppas
with lag time drug release model (Equation (2)). Legend: PCL(5K)0BA (white squares), PCL(5K)50BA (black triangles),
PCL(10K)50BA (white triangles), PCL(5K)75BA (black circles), and PCL(10K)75BA (white circles).
The addition of the porogen during the scaffold processing had a significant effect on
the drug release kinetics (Figure 5). Scaffolds processed in the presence of porogen had a
faster drug release kinetics (Figure 5, right). This effect was even more pronounced if the
porogen-to-PCL weight ratio was increased from 1:1 to 3:1, regardless of the drug content
used (5 or 10 wt.%). In general, scaffold porosity and pore size distribution are among the
main factors influencing the release profiles of drugs in medicated scaff lds [42,48]. The
higher porosities and larger pore sizes obt ined for the scaffolds processed with poroge s
favor the accessibility of the aqueous fluid medium throughout the porous structure f th
scaffold, thus accelerating the drug rele se, notably dur the first hours.
Drug release pr files were fitted to the Korsmeyer-Pepp s with lag time equa ion
model (Equation (2)) with good correlation lev ls (Table 2). The kinetic coefficient k was
si nificantly incre ed in the presence of porogen, confirming th influence of BA in
accelerating the drug release. Interestingly, k was much highe for scaffolds with higher
ketoprofen contents (PCL(10K)50BA and PCL(10K)75BA). The use of porogen did not hav
an influence in the initial r ease time (ca. 0.50 h), since similar tlag values were obtained
for scaffolds processed with different BA contents and even in the absence of the porogen
(0.45 h). n values were below 0.45 in all cases suggesting a complex iffusion-controlled
release mechanism f the drug through the polymeric matrix and the pores filled with the
PBS medium [14,49]. The kinetics of ketoprofen-loaded scaffolds of PCL using BA porogen
were much faster than that reported for PCL-scaffolds prepared by sc-foaming with starch
aerogel microparticles as porogen and at the same drug content [42]. The faster release
with BA porogen was related to a higher porosity and mean pore size with respect to the
use of starch aerogel porogen.
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Table 2. Kinetic fitting parameters to the Korsmeyer-Peppas with lag time drug release model
(Equation (2)) of ketoprofen released from PCL-scaffolds obtained by sc-foaming in PBS pH 7.4
medium at 37 ◦C and 60 rpm.
Scaffold k (hn) tlag (h) n R2
PCL(5K)0BA 0.196 ± 0.012 0.454 ± 0.057 0.404 ± 0.019 0.978
PCL(5K)50BA 0.310 ± 0.020 0.499 ± 0.002 0.231 ± 0.017 0.930
PCL(10K)50BA 0.380 ± 0.022 0.499 ± 0.002 0.188 ± 0.015 0.914
PCL(5K)75BA 0.322 ± 0.026 0.500 ± 0.002 0.222 ± 0.021 0.886
PCL(10K)75BA 0.424 ± 0.021 0.500 ± 0.001 0.165 ± 0.013 0.921
2.3. PCL-Scaffold Degradation Studies
Scaffolds were evaluated regarding their porous structures and weight losses after
21 days in PBS pH 7.4 medium. Weight losses in the scaffolds were higher than those as-
signed to the release of the drug payload (Figure 6). This discrepancy in weight was related
to PCL degradation and erosion and was higher for PCL(10K)50BA and PCL(10K)75BA
scaffolds with higher drug contents (10 wt.%). PCL erosion takes place through hydrolytic
chain scission of the ester groups and the process is favored with higher porosities [50,51].
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The porogen content had a significant impact (p < 0.05) in the weight losses of the 
scaffolds after 7 and 21 days, except for unloaded PCL scaffolds (Figure 5). For instance, 
scaffolds with the same ketoprofen content suffered an increased degradation of ca. 7% 
after 21 days when the porogen content was higher. The morphology, porous structure 
and surface roughness of the scaffolds were almost unaltered after the in vitro degrada-
tion test for three weeks (Figures 7 and 8). Moreover, PCL-based scaffolds might undergo 
faster degradation rates in vivo than under in vitro conditions [52]. 
 
Figure 7. SEM-images of cross sections of (a–c) PCL(5K)50BA and (d–f) PCL(10K)50BA polymeric 
scaffolds loaded with 5 and 10 wt.% of ketoprofen, respectively, after 21 days in PBS pH 7.4 me-
dium. Insets in (a,d): Optical micrographs of the scaffolds. Scale bars (a,d): 200 µm; (b,c,e,f) 100 
µm; (insets) 1 mm. 
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ft r s hen the porogen content was higher. The morphology, porous structure and
surface roughness of the scaffolds were almost unaltered after the in vitro degradation test
for three weeks (Figures 7 and 8). Moreover, PCL-based scaffolds might undergo faster
degradation rates in vivo than under in vitro conditions [52].
2.4. Cytotoxicity Tests
In vitro cell viability tests of murine fibroblasts in the presence of PCL-based scaffolds
were evaluated in the formulations with the lower porogen contents (50 wt.%) due to their
improved mechanical performance. After 24 h of incubation, all formulations presented
excellent cytocompatibility with values close to 100% and similar to the control (p < 0.05)
(Figure 9). Therefore, no remnants of BA were still in the polymeric matrix, since externally
added ammonia is known to reduce the growth rate of mammalian cell lines even at low
concentrations (2–3 mM). This phenomenon occurs through the disruption of intracellular
and intraorganelle pH, ultimately perturbing electrochemical gradients or by direct interac-
tion with enzymes [53]. Excellent cytocompatibility was also obtained after 48 h of direct
incubation with the manufactured PCL-based scaffolds.
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3. Materials and Methods
3.1. Materials
Poly(ε-caprolactone) (PCL; powder, Mw = 50 kDa, Tm = 61.4 ◦C, 66.7% crystallinity)
was purchased from Polysciences (Warrington, PA, USA). Ammonium bicarbonate (BA;
NH4HCO3; 30% minimum content in NH3) from Panreac (Castellar del Vallès, Spain) was
used as porogen. Ketoprofen (K; Tm = 95.8 ◦C, 99.7% purity) was provided by Acofarma
(Terrassa, Spain). CO2 (purity > 99.9%) was provided by Praxair, Inc. (Madrid, Spain) and
used as foaming agent.
3.2. Macroporous PCL-Ketoprofen Composite Scaffold Preparation
Firstly, BA was sieved and the particles of size in the 250–500 µm range were collected
for further use. Ketoprofen-loaded PCL-scaffolds were prepared from formulations with
different PCL:BA:K weight ratios (Table 1). For each scaffold, 1.3 g of the initial compo-
nents were dosed in cylindrical (length = 24.6 mm, inner diameter = 17 mm) Teflon molds
(Brand GmbH, Wertheim, Germany), manually mixed using a spatula and further com-
pacted with an aluminum plunger. Molds were then placed in a high-pressure autoclave
(Thar Technologies, Pittsburgh, PA, USA) and subjected to the sc-foaming process through
a pressurization-soaking-single depressurization protocol [42]. Briefly, the autoclave was
filled with CO2 at the mass flow rate of 5 g/min until the target supercritical conditions of
37 ◦C and 140 bar were achieved. After 1 h in the static mode, the system was depressurized
at a rate of 3 bar/min until atmospheric pressure.
The obtained scaffolds were collected and placed in a vacuum oven (W.C. Her-
aeus GmbH, Hanau, Germany) at 37 ◦C and 100 mmHg for porogen removal through ther-
mal decomposition. Scaffolds were weighed periodically until their weight was constant,
i.e., the porogen leaching process was complete. The same procedure but at atmospheric
pressure was also tested for the sake of comparison. Drug-loaded scaffolds were denoted
as PCL(xK)yBA, being x and y the ketoprofen and BA contents in weight percentage with
respect to PCL content and to the total weight, respectively.
3.3. In Situ Visual Follow-Up of the Supercritical Foaming of Scaffolds
A borosilicate vessel (length = 12 mm, internal diameter= 16.5 mm) filled with 1 g of
PCL was placed within the foaming autoclave and then the standard sc-foaming protocol
(cf. Section 3.2) was carried out. A borescope endoscope (Flylink Technology Co., Shenzhen,
Guangdong, China) was placed pointing at one of the sapphire windows of the foaming
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autoclave to visually follow-up the thermophysical events taking place within the autoclave
through image sequences.
3.4. Structural and Physicochemical Characterization of the Scaffolds
The dimensions and weight of the scaffolds were measured after removal of the porogen
to determine the bulk density (ρbulk) from three replicates. The skeletal density (ρskel) of the
scaffolds was determined by helium pycnometry (Quantachrome, Boynton Beach, FL, USA)
from six replicates and measured at 25 ◦C and 1.01 bar. Overall porosity values (ε) were







The morphological properties of the scaffolds were assessed before and after the
drug release studies (cf. Section 3.5) by digital imaging using a CCD Microscope Camera
(DFC7000 T, Leica, Wetzlar, Germany) and scanning electron microscopy (SEM; EVO LS15,
Zeiss, Oberkochen, Germany). Prior to imaging, scaffolds were cut with a scalpel.
Thermal properties of the scaffolds were analyzed by differential scanning calorimetry
(DSC-Q100, TA Instruments, New Castle, DE, USA) under a nitrogen atmosphere with two
heating cycles up to 200 ◦C under a rate of 10 ◦C/min with an intermediate cooling cycle
down to −10 ◦C.
The mechanical behavior of PCL-scaffolds was analyzed through orthogonal compres-
sion tests using a 30 kg load cell (TA.XTPlus, Stable Micro Systems, Ltd., Godalming, UK)
at a crosshead speed of 1 mm/min until a strain rate of ca. 30%. All the experiments were
performed at 20 ◦C, atmospheric pressure and in duplicate.
3.5. Ketoprofen Release Studies
Scaffolds were cut in pieces of 10 mg after porogen removal and suspended in flasks
containing 50 mL of PBS pH 7.4 solution as release medium. Release studies were performed
under sink conditions (ketoprofen solubility in PBS, pH 7.4 and 37 ◦C = 2.2 mg/mL [54]).
Flasks were placed in an oscillating bath (Unitronic 320 OR, Selecta, Barcelona, Spain) at 37 ◦C
under an agitation of 60 rpm for 21 days. Aliquots (3 mL) were sampled from the release
medium period at selected times. The withdrawn volumes were replaced in the medium
with fresh PBS solution. Samples were filtered (0.2 mm nylon filters) and then the ketoprofen
content in the solution was measured by UV–Vis spectrophotometry (8453, Agilent, Santa
Clara, CA, USA) at the wavelength of 260 nm [42]. Ketoprofen standard solutions in PBS
were performed at concentration ranging from 0.001 to 0.025 mg/mL (R2 > 0.999). Release
tests were performed in triplicate. Once the release test was finished after 21 days, scaffolds
were collected, washed gently with Milli-Q water, freeze-dried and observed by SEM.
Ketoprofen release data were fitted to the Korsmeyer-Peppas with lag time equation
(Equation (2)) using GraphPad Prism v.6.04 for Windows software (GraphPad Software,






where F is the fraction of drug released at a time t, k is a kinetic coefficient related to the
macromolecular polymeric network structure, tlag is the lag time, and n is the diffusional
exponent.
For the degradation studies, scaffolds (20 mg) were suspended in 1 mL of PBS pH 7.4
solution, collected after a certain time period (7 and 21 days), washed gently with Milli-Q
water, freeze-dried and weighed.
3.6. Cytotoxicity Tests
Murine fibroblasts (CCL-163, ATCC, USA) were employed to evaluate the cytotoxicity of
the manufactured scaffolds. Cells were seeded in 24-well plates (30,000 cells/well) with DMEM
medium supplemented with 10 % FBS and 1 % penicillin (10,000 UI/mL)/streptomycin
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(10,000 µg/mL). Culture plate was maintained at 37 ◦C in a humidified atmosphere enriched
with 5% CO2 for 6 h to allow the cell attachment to the bottom of the well.
Prior to seeding, cubic scaffold pieces were sterilized by soaking in EtOH 70% (v/v) for
3 min, followed by drying in a laminar flow cabinet at room temperature. Afterwards, scaffolds
were incubated with cells in quadruplicate for 24 and 48 h at 37 ◦C in a humidified atmosphere
with 5% CO2. Controls included cells incubated without material (negative control).
Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8) (Roche, Basel,
Switzerland) at 24 and 48 h and performed according to the manufacturer’s protocol.
Absorbance was read at the wavelength of 450 nm (UV BioRad Model 680 microplate
reader, Hercules, CA, USA). Cell viability (%) was calculated as follows:





Statistical analyses (1-way ANOVA) of the weight loss after the degradation test and
of the cell viability tests were performed using Statistica v8.0 software (StatSoft Inc., Tulsa,
OK, USA) followed by the post hoc Tukey’s HSD multiple comparison test.
4. Conclusions
An innovative processing approach has been developed to obtain drug-loaded scaf-
folds by supercritical foaming coupled with solid porogen removal avoiding the critical
step of solvent leaching of the said porogen along with the drug. Supercritical foaming
technology opens up new processing possibilities to obtain scaffolds at low operating
temperatures (37 ◦C). The use of ammonium bicarbonate as porogen allowed its removal
from the polymeric scaffolds through thermal degradation at similar temperatures as
the foaming process. The incorporation of BA as a porogen in the scaffold formulation
resulted advantageous in obtaining a second pore family in the required pore size range for
regenerative medicine purposes and assisted the supercritical foaming process to engineer
scaffolds with dual porosity. This solvent-free technology offers a variety of possibilities
of tuning porosity and pore sizes in medicated scaffolds through the porogen content
and size, respectively. In addition, the PCL-based scaffolds were cytocompatible with
murine fibroblast cells after 48 h of direct contact. Finally, the low processing temperature
used allows the technical feasibility of the production of polymeric foams incorporating
thermally-sensitive bioactive agents.
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Appendix A
Table A1. Thermal properties of PCL-based scaffolds under sc-foaming conditions followed by
thermal porogen leaching.
1st Heating Cycle 2nd Heating Cycle
Scaffold Tm (◦C) ∆H (J/g) Crystallinity (%) Tm (◦C) ∆H (J/g) Crystallinity (%)
PCL(0K)0BA 63.70 84.5 59.5 55.80 60.3 42.5
PCL(5K)50BA 61.74 97.6 72.4 53.02 76.2 56.5
PCL(10K)50BA 61.29 96.1 75.2 52.76 70.4 55.1
PCL(5K)75BA 62.67 100.9 74.8 54.65 75.1 55.7
PCL(10K)75BA 61.74 91.4 71.5 54.72 79.7 62.3
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